Drug Trial Radar · NCT05916339
AWARE: Management of ADHD in Autism Spectrum Disorder
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Oct 1, 2023
Primary completion
Jan 1, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Daniel CouryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute; University of California, Irvine; Holland Bloorview Kids Rehabilitation Hospital; University of Rochester; Nationwide Children's Hospital; Children's Hospital Medical Center, Cincinnati; University of Virginia; University of Alberta; Massachusetts General Hospital; MaineHealth; University of Michigan; University of Pittsburgh; Children's Hospital of Philadelphia; Children's Hospital Los Angeles; Prisma Health-Upstate
- First posted
- Jun 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
Conditions
- ADHD
- Autism Spectrum Disorder
Interventions
Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medicationDrug
Amphetamine (AMP) medication names: Adderall, Adderall XR, Adzenys ER, Adzenys XR-ODT, Dayanavel XR, Dexedrine (spansule), Dexedrine (tablet), Mydayis, Procentra liquid Methylphenidate (MPH) medication names: Adhansia XR, Aptensio XR, Azstarys, Concerta, Cotempla XR-ODT, Daytrana, Focalin, Focalin XR, Jornay PM. Metadate CD, Methylin (liquid), Ritalin, Ritalin LA, Quillichew ER, Quillivant XR (liquid)
Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.Drug
If first line stimulant therapy (Amphetamine/Methylphenidate) is deemed not effective or tolerable, re-randomization to the alternate stimulant or alpha-2 agonist will occur. If participant is satisfied with first line stimulant treatment, first-line stimulant therapy will continue. Catapres, Clonidine, Guanfacine, Intuniv, Kapvay, Tenex
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Vanderbilt Parent Rating ScaleTime frame: 16 Weeks
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Maine Medical Center
Portland, Maine · Recruiting
Massachusetts General Hospital Lurie Center for Autism
Boston, Massachusetts · Recruiting
University of Rochester
Rochester, New York · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Prisma Health Upstate
Greenville, South Carolina · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
University of Alberta, Glenrose Rehabilitation Hospital
Edmonton, Canada · Recruiting
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.